Medincell Stock Drops Nearly 3% and Slips to the Lower End of the SBF 120
The biotech company from Montpellier experiences another downturn during the session, contrary to an almost stagnant broader index. The stock continues its decline to the lower end of the SBF 120, following the erosion that began earlier in the week. The decline occurs in a market environment strained by renewed tensions in the Middle East and a surge in Brent crude prices.
A Decline Anchoring at the Tail End of the SBF 120 Despite Well-Oriented Moving Averages
Medincell's stock drops 2.92% to €27.92, ranking among the largest declines in the SBF 120 while the broader index edges up by 0.16%. The stock erases part of the rebound that began in late June, with a weekly decline of 4.65%, yet still holds a gain of 26.91% over three months. Despite today's slide, the price remains above its three moving averages, with a gap of 2.99% over the MM20 (€27.11) and 3.71% over the MM50 (€26.92). The RSI at 56 remains in the neutral zone, indicating no immediate pressure. The session unfolds in a market context weighed down by renewed tensions between the United States and Iran, with Brent crude jumping about 5.2% to $78.02 and the CAC 40 slightly up by 0.22%. The stock once again encounters resistance at the €29.56 mark, a barrier identified and unsuccessfully tested last week. The support at €24.08 remains more than 13% away, providing a cushion before any adverse technical signal.
Uzedy Royalties Pivot, Awaiting the Launch of Olanzapine LAI in Q4 2026
Fundamentally, today's movement follows the announcement of the annual accounts for 2025/2026 revealed on June 16, which triggered a 13.5% drop at the opening the next day. Uzedy royalties (risperidone) had increased by 42% to €9.3 million, but the net loss had deepened to €31.3 million from €18.4 million a year earlier, reflecting accelerated R&D expenses. Among the opportunities highlighted in the June 16, 2026 publication, the company pointed to the commercial launch of Olanzapine LAI expected in the fourth quarter of 2026 and the continued increase in Uzedy royalties. Among the risks identified were the absence of exceptional revenues comparable to those of the previous year and the planned increase in operating expenses to fund expansion. The next observable milestone remains the Q4 2026 deadline, with the crossing of the €29.56 resistance as the next technical milestone.
